NEW YORK, Dec. 19, 2017 /PRNewswire/ -- In keeping with the commitment to dynamically provide members with timely information, WallStEquities.com has issued free tailored Stock Review on PTLA, SRPT, PACB, and BLUE which is a click away at www.wallstequities.com/registration. Research coverage has been initiated by WallStEquities.com on Portola Pharmaceuticals Inc. (NASDAQ: PTLA), Sarepta Therapeutics Inc. (NASDAQ: SRPT), Pacific Biosciences of California Inc. (NASDAQ: PACB), and bluebird bio Inc. (NASDAQ: BLUE). Biotechnology companies are engaged in the R&D of biological substances, primarily for the purpose of drug discovery and diagnostic development. The majority of their revenue is derived from either the sale or licensing of drugs and diagnostic tools. Get you free stock reports on these stock by registering now on Wall St. Equities at: www.wallstequities.com/registration
On Monday, shares in California headquartered Portola Pharmaceuticals Inc. recorded a trading volume of 714,344 shares. The stock ended the session 1.23% higher at $47.60. The Company's shares have surged 112.12% on an YTD basis. The stock is trading 2.18% below its 200-day moving average. Moreover, shares of Portola Pharma, which develops and commercializes therapeutics for patients in the areas of thrombosis, other hematologic disorders, and inflammation, have a Relative Strength Index (RSI) of 41.98.
On December 01st, 2017, research firm Goldman initiated a 'Buy' rating on the Company's stock, with a target price of $75 per share.
On December 12th, 2017, Portola Pharmaceuticals announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has requested additional information related to the Marketing Authorization Application for betrixaban. CHMP has provided the Day 195 List of Outstanding Issues to the Company, with a request for responses during the next available submission window of January 23rd, 2018. Based on this new timeline, the Company expects CHMP to issue an opinion later in the first quarter of 2018. Get started with a complimentary subscription and access to the free report on PTLA at: www.wallstequities.com/registration/?symbol=PTLA
Cambridge, Massachusetts headquartered Sarepta Therapeutics Inc.'s stock closed the day 2.83% higher at $54.09 with a total trading volume of 1.54 million shares. The Company's shares have advanced 18.18% in the previous three months and 97.19% since the start of this year. The stock is trading 2.50% and 34.85% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Sarepta Therapeutics, which focuses on the discovery and development of RNA-based therapeutics for the treatment of rare neuromuscular diseases, have an RSI of 51.55.
On December 01st, 2017, research firm H.C. Wainwright initiated a 'Buy' rating on the Company's stock, with a target price of $75 per share.
On December 05th, 2017, Sarepta Therapeutics announced the election of biopharmaceutical veteran Michael W. Bonney to its Board of Directors. Mr. Bonney was the CEO of Cubist Pharmaceuticals from 2003, through its acquisition by Merck in 2014. He is currently the CEO and Chair of Kaleido Biosciences, a biotechnology company focused on the development of novel chemistries to unlock the power of the human microbiome. Free research on SRPT can be accessed at: www.wallstequities.com/registration/?symbol=SRPT
Pacific Biosciences of California
Shares in Menlo Park, California headquartered Pacific Biosciences of California Inc. recorded a trading volume of 935,565 shares, which was higher than their three months average volume of 820,730 shares. The stock ended yesterday's trading session 3.01% higher at $2.74. The Company's shares are trading below their 50-day moving average by 21.80%. Furthermore, shares of the Company, which designs, develops, and manufactures sequencing systems to resolve genetically complex problems, have an RSI of 32.61. Visit WallStEquities.com now and sign up for the free research on PACB at: www.wallstequities.com/registration/?symbol=PACB
Cambridge, Massachusetts headquartered bluebird bio Inc.'s stock finished Monday's session 0.77% higher at $184.35 with a total trading volume of 800,049 shares. The Company's shares have advanced 15.11% in the last one month, 41.48% over the previous three months, and 198.78% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 19.24% and 62.50%, respectively. Additionally, shares of bluebird bio, which focuses on developing transformative gene therapies for severe genetic diseases and cancer, have an RSI of 61.97.
On December 12th, 2017, bluebird bio announced the pricing of an underwritten public offering of 3,243,244 shares of its common stock at a public offering price of $185 per share, before underwriting discounts. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 486,486 shares of common stock. All of the shares in the offering are to be sold by the Company.
On December 13th, 2017, research firm Barclays reiterated its 'Overweight' rating on the Company's stock with an increase of the target price from $162 a share to $209 a share. The free technical report on BLUE is available at: www.wallstequities.com/registration/?symbol=BLUE
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +21-32-044-483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Wall St. Equities